We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

45 hedge funds and large institutions have $3.53M invested in Protalix BioTherapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 20 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more call options, than puts

Call options by funds: $62K | Put options by funds: $37K

3.02% less ownership

Funds ownership: 7.69% → 4.67% (-3%)

32% less funds holding

Funds holding: 66 → 45 (-21)

47% less capital invested

Capital invested by funds: $6.6M → $3.53M (-$3.07M)

75% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 20

78% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 27

Holders
45
Holders Change
-21
Holders Change %
-31.82%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
5
Reduced
20
Closed
27
Calls
$62K
Puts
$37K
Net Calls
+$25K
Net Calls Change
-$95K

Top Buyers

Rank Fund Capital Flow
1
SWP
Stratos Wealth Partners
Ohio
+$284K
2
Renaissance Technologies
Renaissance Technologies
New York
+$159K
3
Citadel Advisors
Citadel Advisors
Florida
+$77K
4
VF
Virtu Financial
New York
+$45.6K
5
SA
Sanctuary Advisors
Indiana
+$39K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$460K
2
Goldman Sachs
Goldman Sachs
New York
-$433K
3
Northern Trust
Northern Trust
Illinois
-$390K
4
Jane Street
Jane Street
New York
-$257K
5
YIH
Y-Intercept (HK)
Hong Kong
-$185K
Name Holding Trade Value Shares
Change 		Change in
Stake
AQR Capital Management
51
AQR Capital Management
Connecticut
– -$66.8K -57,106 Closed
TSS
52
Two Sigma Securities
New York
– -$61.2K -52,320 Closed
Mirae Asset Global ETFs Holdings
53
Mirae Asset Global ETFs Holdings
Hong Kong
– -$40K -34,167 Closed
Franklin Resources
54
Franklin Resources
California
– -$39.7K -33,892 Closed
SSA
55
Schonfeld Strategic Advisors
New York
– -$32.6K -27,900 Closed
EI
56
Ethic Inc
New York
– -$23.4K -20,039 Closed
RhumbLine Advisers
57
RhumbLine Advisers
Massachusetts
– -$20.7K -17,666 Closed
JF
58
Jump Financial
Illinois
– -$16.6K -14,224 Closed
Balyasny Asset Management
59
Balyasny Asset Management
Illinois
– -$15.6K -13,299 Closed
SC
60
Savant Capital
Illinois
– -$14K -11,996 Closed
CFP
61
Cascade Financial Partners
California
– -$13K -11,100 Closed
EI
62
Ellevest Inc
New York
– -$12.3K -10,494 Closed
Fidelity Investments
63
Fidelity Investments
Massachusetts
– -$7.95K -6,791 Closed
Macquarie Group
64
Macquarie Group
Australia
– -$4.05K -3,460 Closed
PNC Financial Services Group
65
PNC Financial Services Group
Pennsylvania
– -$1.66K -1,418 Closed
Citigroup
66
Citigroup
New York
– -$1.53K -1,307 Closed
Royal Bank of Canada
67
Royal Bank of Canada
Ontario, Canada
– -$1K -1,244 Closed
Carson Wealth (CWM LLC)
68
Carson Wealth (CWM LLC)
Nebraska
– -$1K -845 Closed
New York State Common Retirement Fund
69
New York State Common Retirement Fund
New York
– -$649 -555 Closed
Russell Investments Group
70
Russell Investments Group
United Kingdom
– -$607 -519 Closed
Nisa Investment Advisors
71
Nisa Investment Advisors
Missouri
– -$400 -342 Closed
FFA
72
Farther Finance Advisors
California
– -$99 -85 Closed
1 2
3

PLX Hedge Fund Activity: Q3 2024 in Review

45 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2024, worth a combined $3.53M — down 47% from $6.6M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of PLX and 6 opened new positions — a net loss of 21 holders — while 20 trimmed existing stakes and 5 added.

The largest buyer was Stratos Wealth Partners, opening a new position worth an estimated $284K. The largest seller was Millennium Management, cutting an estimated $460K.

  • 45 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2024, down from 66 in Q2 2024.
  • Funds reported $3.53M of Protalix BioTherapeutics stock for Q3 2024, down 47% quarter-over-quarter.
  • 6 funds opened new Protalix BioTherapeutics positions in Q3 2024 and 27 closed out, a net change of -21 holders.
  • The largest Protalix BioTherapeutics buyer in Q3 2024 was Stratos Wealth Partners, an estimated $284K added.
  • The largest Protalix BioTherapeutics seller in Q3 2024 was Millennium Management, an estimated $460K sold.

Based on aggregated 13F filings for Q3 2024.